Association of functional thrombin‐activatable fibrinolysis inhibitor (TAFI) with conventional cardiovascular risk factors and its correlation with other hemostatic factors in a Spanish population

Abstract

Our aim was to determine the associations of functional thrombin-activatable fibrinolysis inhibitor (TAFI) levels in plasma with conventional cardiovascular risk factors, sex and age, and possible correlations with other hemostatic factors in a Spanish population. We included 303 individuals from a Spanish population. Hemostatic factors such as von Willebrand Factor, VII ag, VIIIc, XIc, XIIc, APCR, protein S, protein C, antithrombin, fibrinogen, and t-PA antigen were assayed. The functional TAFI assay was based on the activation of plasma TAFI with thrombin-thrombomodulin, and the measure of TAFIa activity on the hippuryl-Arg substrate. There were no statistical differences in mean values of functional TAFI among the various female age groups or among the different male age groups, with or without cardiovascular risk factors. Only women younger than 30 years of age showed lower levels of functional TAFI compared to older women. No differences were found among men of different ages. Adjusted for sex and age, hemostatic factors did not show a correlation with functional TAFI levels in plasma. Women with hypercholesterolemia showed higher levels of TAFI; other conventional cardiovascular risk factors did not modify functional TAFI levels either in men or in women. We also found no correlation of functional TAFI levels related to any other hemostatic factors. Am.

Increased plasma thrombin-activatable fibrinolysis inhibitor levels in young obese women with polycystic ovary syndrome

“…This combination of lipid parameters suggests that patients with PCOS may have increased atherogenic potential (29). Some studies reported that thrombin-activatable fibrinolysis inhibitor levels correlated with total cholesterol and women with hypercholesterolemia had higher levels of thrombin-activatable fibrinolysis inhibitor (30,31). Conversely, we were not able to show any correlation between thrombin-activatable fibrinolysis inhibitor and lipid parameters, as previously reported (7,22).…”

Type 2 diabetes as a modifier of fibrin clot properties in patients with coronary artery disease

“…There have been previous studies showing increased [29–31] or decreased TAFI levels [32, 33] in CAD patients. There have been, however, few reports evaluating the effect of TAFI on clot lysis time in diabetic subjects that demonstrated no effect [34] or hypofibrinolysis [35].…”

Curiouser and curiouser: Recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles

“…Thus, the mouse is unlikely to be a useful comparative model for CPB2 gene expression in inflammatory states. Data from clinical studies in humans have shown positive associations between plasma TAFI concentrations and inflammatory markers such as fibrinogen and C-reactive protein [42,45], although other studies have failed to detect such associations [46][47][48]. One study found markedly elevated plasma TAFI concentrations in a group of patients with assorted inflammatory disorders (Behcet's disease, celiac disease, and Reiter's syndrome) [49].…”